Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.55 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.44 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.44 |
| ▸ | RAD52 | P43351 | 1/20 | 0.40 |
| ▸ | IDO1 | P14902 | 1/20 | 0.39 |
| ▸ | CXCR4 | P61073 | 2/20 | 0.38 |
| ▸ | BAX | Q07812 | 1/20 | 0.37 |
| ▸ | DRD2 | P14416 | 2/20 | 0.37 |
| ▸ | DRD3 | P35462 | 2/20 | 0.37 |
| ▸ | POLB | P06746 | 2/20 | 0.36 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | BRD4 | O60885 | 1/20 | 0.35 |
| ▸ | PADI1 | Q9ULC6 | 1/20 | 0.35 |
| ▸ | PADI4 | Q9UM07 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Piperazine SCHEMBL28217692 | 1.00 | SMN1; SMN2 (0.55) | SMN1; SMN2CHRM5CHRM3RAD52IDO1 | |
| Hydrochloric Acid SCHEMBL21178220 | 0.98 | SMN1; SMN2 (0.58) | SMN1; SMN2CHRM5CHRM3RAD52IDO1 | |
| Hydrochloric Acid SCHEMBL8296060 | 0.98 | SMN1; SMN2 (0.58) | SMN1; SMN2CHRM5CHRM3RAD52IDO1 | |
| SCHEMBL13833167 | 0.98 | SMN1; SMN2 (0.56) | SMN1; SMN2CHRM5CHRM3RAD52IDO1 | |
| SCHEMBL1974799 | 0.98 | SMN1; SMN2 (0.56) | SMN1; SMN2CHRM5CHRM3RAD52IDO1 | |
| SCHEMBL1393824 | 0.98 | SMN1; SMN2 (0.56) | SMN1; SMN2CHRM5CHRM3RAD52IDO1 | |
| SCHEMBL154268 | 0.98 | SMN1; SMN2 (0.56) | SMN1; SMN2CHRM5CHRM3RAD52IDO1 | |
| SCHEMBL10667505 | 0.98 | SMN1; SMN2 (0.56) | SMN1; SMN2CHRM5CHRM3RAD52IDO1 | |
| SCHEMBL22014102 | 0.95 | SMN1; SMN2 (0.55) | SMN1; SMN2CHRM5CHRM3RAD52IDO1 | |
| SCHEMBL20565492 | 0.95 | SMN1; SMN2 (0.55) | SMN1; SMN2CHRM5CHRM3RAD52IDO1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2019143073-A1 | GADOTERIDOL INTERMEDIATE AND METHOD FOR PREPARING GADOTERIDOL USING SAME | 주식회사 엔지켐생명과학 | 2019-07-25 | — | — | WO | claimed |
| WO-2024085723-A1 | FERRITIN PROTEIN STRUCTURE DISPLAYING SARS-COV-2 S1-DERIVED PROTEIN AND ANTIBODY FC REGION PROTEIN SIMULTANEOUSLY ON SURFACE, AND USE THEREOF FOR VACCINE FOR CORONAVIRUS SARS-COV-2 | 충남대학교 산학협력단 | 2024-04-25 | — | — | WO | disclosed |
| US-11905257-B2 | Manufacturing process for preparing gadoteridol | BRACCO IMAGING S.P.A. (IT) | 2024-02-20 | — | — | US | disclosed |
| WO-2023245169-A1 | ANTIMICROBIAL PEPTIDE COMBINATIONS | Vestaron Corporation (US) | 2023-12-21 | — | — | WO | disclosed |
| WO-2023245100-A1 | ANTIMICROBIAL NCR13 VARIANT PEPTIDES | Vestaron Corporation (US) | 2023-12-21 | — | — | WO | disclosed |
| US-20230391735-A1 | MANUFACTURING PROCESS FOR PREPARING GADOTERIDOL | BRACCO IMAGING S.P.A. (IT) | 2023-12-07 | — | — | US | disclosed |
| CN-114085192-B | Refining method of gadoteridol intermediate | 海南普利制药股份有限公司 | 2023-09-19 | — | — | CN | disclosed |
| CN-116209679-A | Antibody-drug conjugates containing anti-mesothelin antibodies and uses thereof | 财团法人生物技术开发中心 | 2023-06-02 | — | — | CN | disclosed |
| CN-114105897-B | Preparation method of gadoteridol | 安徽普利药业有限公司 | 2023-04-04 | — | — | CN | disclosed |
| CN-109952375-B | Novel anti-human MUC1 antibody Fab fragment | 安斯泰来制药株式会社 | 2022-11-18 | — | — | CN | disclosed |
| WO-2019143073-A1 | GADOTERIDOL INTERMEDIATE AND METHOD FOR PREPARING GADOTERIDOL USING SAME | 주식회사 엔지켐생명과학 | 2019-07-25 | — | — | WO | disclosed |
| WO-2018138280-A1 | NANOMATERIAL AND METHOD OF PRODUCTION OF A NANOMATERIAL FOR MEDICAL APPLICATIONS, SUCH AS MRI OR SERS | UNIVERSITE PARIS NORD (FR) | 2018-08-02 | — | — | WO | disclosed |
| EP-2766364-A1 | FOLATE CONJUGATES OF ALBUMIN-BINDING ENTITIES | Merck & Cie (CH) | 2014-08-20 | — | — | EP | disclosed |
| WO-2013024035-A1 | FOLATE CONJUGATES OF ALBUMIN-BINDING ENTITIES | Merck & Cie (CH) | 2013-02-21 | — | — | WO | disclosed |
| EP-2170406-A2 | A METHOD OF HYPERPOLARISING A MAGNETIC RESONANCE AGENT | Gadian, David (GB) | 2010-04-07 | — | — | EP | disclosed |
| WO-2009004357-A2 | A METHOD OF HYPERPOLARISING A MAGNETIC RESONANCE AGENT | UNIVERSITY COLLEGE LONDON (GB) | 2009-01-08 | — | — | WO | disclosed |
| EP-0545511-B1 | Process for the preparation of mono-N-substituted tetraazamacrocycles | SCHERING AG (DE) | 2002-05-29 | — | — | EP | disclosed |
| US-6380169-B1 | FOR INHIBITING MESSENGER RNA TRANSLATION USING ANTI-SENSE OLIGONUCLEOSIDES CONTAINING 5'-CAP CLEAVAGE MOIETIES | ISIS PHARMACEUTICALS, INC. | 2002-04-30 | — | — | US | disclosed |
| US-5410043-A | Chemical intermediate for metal complexes | SCHERING AKTIENGESELLSCHAFT (DE) | 1995-04-25 | — | — | US | disclosed |
| EP-0545511-A2 | Process for the preparation of mono-N-substituted tetraazamacrocycles | SCHERING AKTIENGESELLSCHAFT (DE) | 1993-06-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230391735-A1 | MANUFACTURING PROCESS FOR PREPARING GADOTERIDOL | SSTR2, GCG, ADCYAP1R1 | SMN1; SMN2 3067/4885CHRM5 1504/4885CHRM3 628/4885 |
| US-11905257-B2 | Manufacturing process for preparing gadoteridol | SSTR2, GCG, ADCYAP1R1 | SMN1; SMN2 3067/4885CHRM5 1504/4885CHRM3 628/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.